<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580564</url>
  </required_header>
  <id_info>
    <org_study_id>KL167-Ⅱ-03-CTP</org_study_id>
    <nct_id>NCT03580564</nct_id>
  </id_info>
  <brief_title>An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma</brief_title>
  <official_title>An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate the efficacy of BGB-A317 a in subjects with relapsed or refractory
      classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano
      Classification
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to 2years</time_frame>
    <description>Overall Response Rate (ORR) defined as the proportion of subjects who achieves a best response of CR or PR, assessed by IRC per the Lugano Classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 2years</time_frame>
    <description>From the first dose of KL-A167 to the date of PD or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 2years</time_frame>
    <description>From the date that response criteria are first met to the date that PD is objectively documented or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2years</time_frame>
    <description>From the first dose of KL-A167 to the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Up to 2years</time_frame>
    <description>From the date of the first dose of KL-A167 to the time the response criteria are first met</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL-A167</intervention_name>
    <description>KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

          -  Histopathological confirmed classical Hodgkin's lymphoma

          -  Relapsed/refractory cHL include：subject with no response to or with progression after
             ASCT ；subject which failed failed second line and above chemtherapy；subject which
             didn't achieve PR after 2 cycles or didn't achieve CR after 4 cycles

          -  At least one measurable disease (long axis&gt;15 mm and short axis&gt;5 mm,or both axis&gt;10
             mm）

          -  ECOG performance status of 0 or 12

          -  Subject must have adequate organ functions and meet requirements on laboratory
             values.：Count of Blood Cells: absolute neutrophil count (ANC) ≥ 1.0 × 109 / L;
             platelet count (PLT) ≥ 50 × 109 / L; hemoglobin content (HGB) ≥ 7.0 g / Dl; Liver
             function: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN); alanine
             aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN，with the
             exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients
             with hepatic metastases or Gilbert's syndrome (total bilirubin ≤ 3 × ULN)Renal
             function: serum creatinine (Cr) ≤ 1.5 × ULN or Creatinine clearance rate（CCR）≥50
             mL/min；International normalized ratio (INR) ≤ 1.5 x ULN ；Thyroid function: thyroid
             stimulating hormone (TSH) in normal range.

          -  Prior chemotherapy, radiotherapy, immunotherapy or investigational therapy (including
             Chinese herbal medicine and Chinese patent medicine) used to control cancer including
             locoregional treatment must have been completed ≥ 4 weeks before the first dose of
             KL-A167(Mitomycin or nitroso must have been completed ≥ 6 weeks), and all
             treatment-related adverse events (except alopecia) are stable and have either returned
             to baseline or Grade 0/1

          -  Subjects of reproductive potential must be willing to use adequate contraception
             during the course of the study and through 6 months after the last dose of study
             medication

          -  Subject has voluntarily agreed to participate by giving written informed consent.

        Exclusion Criteria:

          -  Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma.

          -  Known central nervous system lymphoma.

          -  Prior malignancy except for curatively treated carcinoma in situ of the cervix or
             breast ，Superficial bladder cancer，and Squamous cell carcinoma in situ

          -  History of severe hypersensitivity reaction to monoclonal antibodies

          -  Prior exposure to any anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody.

          -  need the other anticancer therapy during the study

          -  Received any anticancer vaccine or other medications for immunomodulatory receptor
             preparations

          -  Received HSCT

          -  Received ASCT in the past 3 months

          -  Serious acute or chronic infection requiring systemic therapy.

          -  Subject with active autoimmune disease or history of autoimmune disease with high risk
             of recurrence.

          -  Conditions requiring systemic treatment with either corticosteroids (&gt; 10 mg daily
             Prednisone equivalent) or other immunosuppressive medications within 14 days of first
             dose of KL-A167

          -  serious medical diseases, ex Suffering from heart failure (New York Heart Association
             standard III or IV), ischemic heart disease (such as myocardial infarction or angina),
             congestive heart failure and other cardiovascular diseases, uncontrolled
             diabetes(fasting blood glucose≥10 mmol/L), uncontrolled high blood pressure(Systolic&gt;
             150 mmHg and / or diastolic&gt; 100 mmHg), LVEF＜50%

          -  QTcF＞450 msec

          -  Known active HBV or HCV infection.

          -  Known HIV infection.

          -  Has history of interstitial lung disease or non-infectious pneumonitis. Subjects with
             prior drug-induced or radiation-induced pneumonitis who are asymptomatic are eligible.

          -  Known active pulmonary tuberculosis

          -  Has history of AE related with immune system during the Immunotherapy

          -  Received a live vaccine within 4 weeks of the first dose of study medication or plan
             to receive live vaccine during study period.

          -  Known neurological or psychiatric diseases

          -  Ongoing alcohol or drug abuse

          -  Pregnancy (absence to be confirmed by serum β-human chorionic gonadotropin test) or
             breastfeeding

          -  Participation in another clinical trial within the past 4 weeks

          -  Other significant disease that in the investigator's opinion should exclude the
             subject from the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dawei Wu</last_name>
    <phone>010-87788268</phone>
    <email>wumingshi-117@163.com</email>
  </overall_contact>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>June 26, 2018</last_update_submitted>
  <last_update_submitted_qc>June 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

